查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000719

急性骨髓性白血病治療市場：2026年至2032年全球預測（依治療方法、作用機制、治療階段、給藥途徑、患者年齡及最終用戶分類）

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Route Of Administration, Patient Age, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，急性骨髓性白血病治療市場價值將達到 11.2 億美元，到 2026 年將成長至 12.5 億美元，到 2032 年將達到 26.1 億美元，年複合成長率為 12.74%。

主要市場統計數據
基準年 2025 11.2億美元
預計年份：2026年 12.5億美元
預測年份：2032年 26.1億美元
複合年成長率 (%) 12.74%

對急性骨髓性白血病治療的發展歷程進行了簡明扼要的基礎性概述，重點在於臨床複雜性、精準醫療方法和商業性需求。

急性骨髓性白血病(AML) 仍然是臨床上最複雜的骨髓惡性腫瘤之一，其特徵是遺傳因素多樣、患者群體異質性高以及治療模式不斷演變。過去十年，治療模式已從廣譜細胞毒性療法轉向精準標靶治療和免疫腫瘤療法。這項轉變的驅動力在於對分子層面疾病認知的加深、診斷分層技術的改進以及先進生技藥品和細胞療法的成熟。因此，研究、臨床實踐和商業領域的各方相關人員面臨著一個快速變化的環境，需要採取適應性策略。

權威地檢驗了科學、監管和商業領域中正在重塑急性骨髓性白血病。

急性髓性白血病（AML）的治療格局正經歷著一場變革，這主要得益於科學進步、監管政策的演變以及商業性創新。基因組分析和微量殘存疾病（MRD）檢測使得患者篩選更加精準，治療策略也更加靈活，精準醫療正從概念走向日常臨床實踐。抗體藥物偶聯物（ADC）和融合蛋白等生技藥品平台的成熟進一步推動了這一轉變，這些平台拓寬了治療指數，並實現了靶向細胞毒性藥物的遞送。同時，細胞療法的研發和規模化生產雖然有望帶來持續的療效，但也對生產和物流提出了獨特的要求。

對貿易政策的累積影響進行清晰分析，以評估其對供應鏈、製造業投資選擇以及 2025 年獲得抗逆轉錄病毒療法等方面的影響。

2025年關稅的引入和貿易政策的轉變對整個急性髓系白血病（AML）治療價值鏈產生了切實的連鎖反應，其累積影響主要體現在供應鏈韌性、生產策略和患者負擔成本趨勢等方面。對於生技藥品和細胞療法生產中依賴進口的組件，例如特種試劑、一次性系統和關鍵設備，採購模式發生了變化，迫使製造商和合約合作夥伴重新評估採購區域和庫存緩衝。為此，多個相關人員加快了近岸外包的步伐，並使其供應商網路多元化，以減輕關稅相關干擾的影響。

全面的細分分析揭示了治療方法類型、作用機制、臨床環境、給藥途徑和患者人口統計特徵如何決定臨床和商業策略。

細分市場分析揭示了每種治療方法類型、作用機制、治療線、最終用戶、給藥途徑和患者年齡層的不同機會和運作要求。治療方式選擇包括多種小分子化合物，例如抗體藥物偶聯物、融合蛋白和單株抗體等生技藥品；細胞療法，包括CAR-T療法和幹細胞移植；基因療法；以及BCL-2抑制劑、 DNA甲基轉移酵素抑制劑和蛋白酪氨酸激酶抑制劑（進一步細分為FLT3和KIT標靶藥物）。這些治療方法的差異對臨床實驗室設計、生產複雜性和核准後證據產生等方面都有不同的影響。

詳細的區域觀點突顯了全球主要市場在採用促進因素、監管預期和營運重點方面的差異。

區域洞察凸顯了美洲、歐洲、中東和非洲以及亞太地區在應用促進因素、監管預期和營運重點方面的差異，這些差異各自以獨特的方式影響臨床開發和商業化。在美洲，分散的支付方環境和複雜的報銷機制，加上強大的臨床實驗室網路和成熟的腫瘤中心，使得證據生成和價值論證對於高階產品的獲取和推廣至關重要。在歐洲、中東和非洲，集中式的法規結構和不斷變化的報銷標準進一步凸顯了健康技術評估 (HTA) 合規性和區域定價策略的重要性。

此方法將科學差異化與以生產規模和支付方為重點的證據產生相結合，從而加強了企業的策略行動和競爭合作。

急性髓系白血病（AML）治療生態系統中的主要企業正在尋求將深厚的科學差異化優勢與切實可行的商業計劃相結合的策略。大型製藥企業正利用其成熟的商業基礎設施和全球開發經驗，加速後期臨床開發項目，同時確保與支付方儘早建立聯繫。中型生物技術公司和專業細胞療法公司則專注於敏捷創新，瞄準分子定義的亞群，並尋求策略合作夥伴關係，以彌補生產能力和全球市場准入方面的差距。在整個產業中，企業正擴大建立合作夥伴關係，將獨特的平台與互補的資產結合，以降低臨床開發風險並擴大複雜生產流程的規模。

為協調臨床開發、生產韌性和支付方參與，以加速提高醫療服務可近性和商業性成功，提出切實可行的策略建議。

產業領導企業應採取一系列切實可行且影響深遠的措施，使研發重點與商業化實際情況相符，同時確保供應鏈的連續性和與支付方的良好關係。首先，優先發展以生物標記主導的臨床管道和適應性測試設計，以降低後期研發風險，並提高獲得監管部門核准和報銷的可能性。其次，加速供應商網路多元化，並考慮區域性生產投資，以減少貿易中斷帶來的影響，縮短病患用藥時間。第三，從研發規劃的早期階段就納入健康經濟學和結果研究，以產生基於價值的合約所需的真實世界數據（REW），並支持差異化定價談判。

為了確保研究結果的可靠性，我們採用了一種透明且嚴謹的混合方法研究方法，結合了對專家的初步訪談、二手文獻綜述和證據檢驗驗證。

本研究採用多層次、可重複的方法，結合定性和定量方法，以確保檢驗的穩健性和三角驗證。主要調查包括對臨床醫生、臨床檢驗醫師、支付方和行業高管進行結構化訪談，以了解臨床實踐、報銷趨勢和營運限制等方面的實際觀點。專家諮詢為供應鏈中斷和監管變化的情境分析提供了見解，而醫生主導的實驗室審查則揭示了真實的治療模式和仿單標示外用藥的背景資訊。

一份簡潔、綜合的總結，強調了臨床、製造和商業策略之間需要協調，才能對病人產生持久的影響。

總之，目前急性髓系白血病（AML）治療的特點是科學創新加速發展、監管機構和支付方的期望不斷變化以及運營複雜性日益增加，所有這些因素共同重塑了患者的就醫管道。成功需要一項整合策略，將分子標靶臨床開發與強大的生產基礎設施、符合支付方要求的證據生成以及本地化最佳化的商業化計劃相結合。積極應對供應鏈漏洞、採用適應性臨床實驗室設計並儘早與支付方溝通的相關人員，更有能力將治療進展轉化為永續的臨床和商業性成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：急性骨髓性白血病治療市場：依治療方法

  • 生技藥品
    • 抗體-藥物偶聯物
    • 融合蛋白
    • 單株抗體
  • 細胞療法
    • CAR-T細胞療法
    • 幹細胞移植
  • 基因治療
  • 低分子化合物

第9章：急性骨髓性白血病治療市場：依作用機轉分類

  • BCL-2抑制劑
  • DNA甲基轉移酵素酶抑制劑
  • HDAC抑制劑
  • 免疫調節劑
  • 蛋白酪氨酸激酶抑制劑

第10章：急性骨髓性白血病治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第11章：急性骨髓性白血病治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第12章：急性骨髓性白血病治療市場：依患者年齡層別分類

  • 成人
  • 老年人
  • 兒童

第13章：急性骨髓性白血病治療市場：依最終用戶分類

  • 醫院藥房
  • 零售藥房
  • 專科診所

第14章：急性骨髓性白血病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：急性骨髓性白血病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：急性骨髓性白血病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國急性骨髓性白血病治療市場

第18章：中國急性骨髓性白血病治療市場。

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.（Otsuka Group）
  • Celgene Corporation
  • CTI BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merus NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company
Product Code: MRR-02026C4C8B97

The Acute Myeloid Leukemia Therapeutics Market was valued at USD 1.12 billion in 2025 and is projected to grow to USD 1.25 billion in 2026, with a CAGR of 12.74%, reaching USD 2.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.12 billion
Estimated Year [2026] USD 1.25 billion
Forecast Year [2032] USD 2.61 billion
CAGR (%) 12.74%

A concise foundational overview of acute myeloid leukemia therapeutic evolution highlighting clinical complexity, precision approaches, and commercial imperatives

Acute myeloid leukemia (AML) remains one of the most clinically complex hematologic malignancies, characterized by heterogeneous genetic drivers, variable patient demographics, and evolving therapeutic paradigms. Over the past decade, the therapeutic landscape has shifted from broadly cytotoxic regimens toward precision-targeted approaches and immuno-oncology modalities. This transition has been driven by deeper molecular understanding, improved diagnostic stratification, and maturation of advanced biologics and cellular therapies. Consequently, stakeholders across research, clinical practice, and commercial functions face a rapidly changing environment that demands adaptive strategies.

Clinicians now balance established induction-maintenance frameworks with an expanding armamentarium of targeted inhibitors, epigenetic modulators, and cell-based interventions. At the same time, payers and provider systems are adapting reimbursement approaches to account for high-cost one-time therapies and long-term outcomes. These dynamics create both opportunities and operational complexities for manufacturers, contract development and manufacturing organizations, and supply-chain partners. Therefore, a clear, actionable synthesis of clinical trends, regulatory shifts, and commercial imperatives is essential for leaders making investment, alliance, and launch decisions in the AML therapeutics arena.

An authoritative examination of the converging scientific, regulatory, and commercial forces reshaping acute myeloid leukemia therapy development and access

The AML therapeutic landscape is experiencing transformative shifts driven by converging scientific advances, regulatory evolution, and commercial innovation. Precision medicine has moved from concept to clinical routine as genomic profiling and minimal residual disease assays enable more refined patient selection and adaptive treatment strategies. This shift is complemented by the maturation of biologic platforms, including antibody drug conjugates and fusion proteins, that extend the therapeutic index and permit targeted cytotoxic delivery. Simultaneously, the development and scaling of cell therapies have introduced durable response potential while imposing unique manufacturing and logistics requirements.

Concurrently, regulatory pathways are evolving to accommodate novel modalities and surrogate endpoints, which accelerates time-to-access but also raises evidentiary demands for long-term safety and real-world effectiveness. Payers are responding with value-based contracting pilots and outcomes-based reimbursement models that link upfront cost to durability of response. Industry partnerships are proliferating to pool expertise across discovery, translational science, and commercial access, altering traditional competitive dynamics. As a result, success increasingly depends on integrated strategies that align clinical development with supply-chain readiness and payer engagement, rather than isolated product-centered plans.

A clear analysis of cumulative trade policy impacts on AML therapeutic supply chains, manufacturing investment choices, and access considerations in 2025

The introduction of elevated tariff regimes and trade policy shifts in 2025 created tangible ripple effects across the AML therapeutics value chain, with cumulative impacts centering on supply-chain resilience, manufacturing strategy, and cost-to-patient dynamics. Import-dependent components used in biologics and cell therapy manufacturing, including specialized reagents, single-use systems, and critical equipment, saw altered procurement profiles that prompted manufacturers and contract partners to reassess sourcing geographies and inventory buffers. In response, several stakeholders accelerated nearshoring initiatives and diversified supplier networks to mitigate exposure to tariff-related disruptions.

Beyond procurement, tariffs influenced capital expenditure decisions for new manufacturing capacity, particularly for complex modalities that require specialized clean-room facilities and cold-chain infrastructure. Firms contemplating new plants weighed increased import duties on equipment and spare parts against long-term strategic imperatives for regional supply security. Moreover, higher landed costs for imported materials exerted pressure on pricing negotiations and distributor agreements, which in turn affected hospital and specialty clinic budgets for oncology therapeutics. These pressures reinforced the need for transparent cost-of-goods analyses and collaborative contracting mechanisms between manufacturers and payers.

Finally, tariffs intensified the focus on regulatory and customs harmonization to reduce administrative delays that compound the financial impact of trade measures. Stakeholders increasingly sought engagement with policymakers and industry associations to clarify tariff classifications for biologic and advanced therapy components, and to advocate for exemptions where national health priorities justified rapid access. As a consequence, companies that proactively adapted procurement strategies, reinforced regional manufacturing footprints, and engaged constructively with policymakers were better positioned to preserve supply continuity and protect patient access amid the changing trade environment.

Comprehensive segmentation analysis revealing how therapy modality, mechanism, care setting, administration route, and patient demographics define clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and operational demands across therapy types, mechanisms, lines of therapy, end users, routes of administration, and patient age cohorts. Therapeutic modality choices span biologic options such as antibody drug conjugates, fusion proteins, and monoclonal antibodies; cell therapies including CAR T approaches and stem cell transplantation; gene therapies; and a range of small molecules where BCL-2 inhibitors, DNA methyltransferase inhibitors, and tyrosine kinase inhibitors, with further subdivision into FLT3 and KIT targeted agents, play a central role. These modality distinctions carry distinct implications for clinical trial design, manufacturing complexity, and post-approval evidence generation.

Mechanism-focused segmentation underscores how BCL-2 inhibition, epigenetic modulation via DNA methyltransferase inhibitors, histone deacetylase modulation, immunomodulatory agents, and tyrosine kinase inhibition differentially influence combination strategies and resistance management. In terms of line of therapy, first-line paradigms prioritize durability and tolerability in newly diagnosed populations, second-line treatments emphasize salvage efficacy and safety, and third-line and beyond options concentrate on overcoming acquired resistance and managing cumulative toxicity. End-user segmentation highlights that hospital pharmacies must coordinate inpatient administration and cold-chain storage for complex biologics, retail pharmacies navigate outpatient dispensing of oral regimens, and specialty clinics deliver advanced cellular therapies under highly controlled conditions.

Route-of-administration segmentation differentiates intravenous therapies that demand infusion infrastructure and monitoring from oral agents that enable at-home dosing but require adherence support, while subcutaneous options can reduce infusion burdens yet require patient education and administration training. Patient age segmentation shows that adult cohorts constitute the bulk of treatment decisions with geriatric populations often necessitating adapted dosing and comorbidity management, whereas pediatric cases require bespoke safety and developmental considerations. Integrating these segmentation lenses enables stakeholders to prioritize clinical development pathways, align manufacturing and distribution investments, and design differentiated market access approaches tailored to modality, mechanism, care setting, and patient demographics.

An in-depth regional perspective highlighting differentiated adoption drivers, regulatory expectations, and operational priorities across major global markets

Regional insights underscore divergent drivers of adoption, regulatory expectations, and operational priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific regions, each presenting unique implications for clinical development and commercialization. In the Americas, fragmented payer landscapes and advanced reimbursement mechanisms coexist with robust clinical trial networks and established oncology centers, creating an environment where evidence generation and value demonstration are critical to premium access and uptake. Conversely, Europe Middle East and Africa encompasses a mix of centralized regulatory frameworks and variable reimbursement thresholds, which heightens the importance of health technology assessment alignment and regional pricing strategies.

Asia-Pacific presents accelerated adoption potential driven by large patient populations, growing diagnostic capabilities, and expanding manufacturing capacity, yet it also features diverse regulatory regimes and cost-sensitivity that necessitate regionalized clinical development plans and flexible commercial models. Across all regions, logistical considerations such as cold-chain robustness, local manufacturing partnerships, and expedited regulatory engagement materially affect launch sequencing and access timelines. Therefore, a regionally nuanced approach that balances centralized global coordination with local execution capacity will optimize patient reach and commercial sustainability.

Strategic company behaviors and competitive alignments that combine scientific differentiation with manufacturing scale and payer-focused evidence generation

Leading companies in the AML therapeutics ecosystem are pursuing strategies that blend deep scientific differentiation with pragmatic commercial planning. Large pharmaceutical organizations are leveraging established commercial infrastructure and global development expertise to accelerate late-stage programs and to secure payer conversations early. Mid-sized biotechs and specialized cell therapy firms focus on nimble innovation, targeting molecularly defined subpopulations and pursuing strategic collaborations to fill capability gaps in manufacturing and global access. Across the board, companies are increasingly forming alliances that combine proprietary platforms with complementary assets to de-risk clinical pathways and to scale complex manufacturing processes.

Manufacturing partners and contract development organizations are scaling capabilities for advanced modalities, investing in single-use technologies, closed-system cell processing, and decentralized fill-finish solutions to support faster patient access. At the same time, market entrants emphasize differentiated clinical trial designs that incorporate biomarker-driven enrollment and adaptive endpoints to generate compelling evidence for regulators and payers. Commercial playbooks reflect a shift toward value-based pricing discussions, outcomes tracking, and integrated service offerings that include diagnostics and patient support. Firms that integrate clinical innovation with supply-chain robustness and payer-aligned evidence generation maintain a competitive advantage in translating scientific promise into sustainable patient access.

Actionable strategic recommendations that align clinical development, manufacturing resilience, and payer engagement to accelerate access and commercial success

Industry leaders should pursue a set of pragmatic, high-impact actions that align R&D priorities with commercialization realities while safeguarding supply continuity and payer relationships. First, prioritize biomarker-driven clinical pathways and adaptive trial designs that de-risk late-stage development and enhance the probability of regulatory approval and reimbursement. Second, accelerate diversification of supplier networks and consider regional manufacturing investments to reduce exposure to trade-related disruptions and to shorten time-to-patient. Third, embed health economics and outcomes research early in development plans to generate the real-world evidence required for value-based contracting and to support differentiated pricing conversations.

Moreover, cultivate cross-sector partnerships that combine discovery platforms with manufacturing and distribution expertise to accelerate scale-up of complex modalities. Invest in digital tools for remote patient monitoring and adherence support, particularly for oral and subcutaneous therapies, to demonstrate real-world effectiveness and to support outcomes-based agreements. Finally, engage proactively with policymakers and payer stakeholders to clarify reimbursement pathways for one-time and high-cost therapies, and to advocate for regulatory harmonization that reduces administrative barriers to timely access. Collectively, these actions will strengthen resilience, expedite access, and align commercial expectations with clinical realities.

A transparent and rigorous mixed-methods research approach combining primary expert interviews, secondary literature review, and evidence triangulation to ensure dependable insights

The research methodology employed a layered and reproducible approach combining both qualitative and quantitative techniques to ensure robustness and triangulation of findings. Primary research included structured interviews with clinicians, clinical trial investigators, payers, and industry executives to capture frontline perspectives on clinical practice, reimbursement dynamics, and operational constraints. Expert consultations informed scenario analyses around supply-chain disruptions and regulatory shifts, while investigator-initiated study reviews provided context for real-world treatment patterns and off-label usage.

Secondary research encompassed a comprehensive review of peer-reviewed literature, clinical trial registries, regulatory guidances, and company disclosures to construct an evidence base for mechanism-specific efficacy and safety profiles. Commercial intelligence was derived from product labeling, conference proceedings, and public tenders to assess accessibility considerations across care settings. Data synthesis applied qualitative coding, comparative framework analysis, and cross-validation against multiple independent sources to reduce bias and to enhance credibility. Throughout, methodological transparency was maintained by documenting data provenance and by subjecting key assumptions to sensitivity checks and expert validation.

A concise integrative synthesis emphasizing coordinated clinical, manufacturing, and commercial strategies required to realize durable patient impact

In conclusion, the AML therapeutics landscape is characterized by accelerated scientific innovation, shifting regulatory and payer expectations, and evolving operational complexities that together redefine pathways to patient access. Success requires integrated strategies that pair molecularly targeted clinical development with resilient manufacturing, payer-aligned evidence generation, and regionally tailored commercialization plans. Stakeholders that proactively address supply-chain vulnerabilities, adopt adaptive clinical designs, and engage payers early will be better equipped to translate therapeutic advances into sustainable clinical and commercial outcomes.

Looking ahead, the intersection of precision diagnostics, advanced biologics, and cell therapies presents substantial promise for improving patient outcomes, provided that industry actors coordinate across scientific, regulatory, and commercial domains. By aligning investments in capability building with strategic partnerships and by embedding health-economic thinking throughout development programs, organizations can navigate complexity and deliver meaningful value to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type

  • 8.1. Biologic
    • 8.1.1. Antibody Drug Conjugates
    • 8.1.2. Fusion Proteins
    • 8.1.3. Monoclonal Antibodies
  • 8.2. Cell Therapy
    • 8.2.1. CAR T Cell Therapy
    • 8.2.2. Stem Cell Transplantation
  • 8.3. Gene Therapy
  • 8.4. Small Molecule

9. Acute Myeloid Leukemia Therapeutics Market, by Mechanism Of Action

  • 9.1. BCL-2 Inhibitors
  • 9.2. DNA Methyltransferase Inhibitors
  • 9.3. HDAC Inhibitors
  • 9.4. Immunomodulatory Agents
  • 9.5. Tyrosine Kinase Inhibitors

10. Acute Myeloid Leukemia Therapeutics Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Acute Myeloid Leukemia Therapeutics Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Acute Myeloid Leukemia Therapeutics Market, by Patient Age

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Acute Myeloid Leukemia Therapeutics Market, by End User

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy
  • 13.3. Specialty Clinic

14. Acute Myeloid Leukemia Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Acute Myeloid Leukemia Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Acute Myeloid Leukemia Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Acute Myeloid Leukemia Therapeutics Market

18. China Acute Myeloid Leukemia Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Actinium Pharmaceuticals, Inc.
  • 19.7. Agios Pharmaceuticals, Inc.
  • 19.8. Amgen Inc.
  • 19.9. Astellas Pharma Inc.
  • 19.10. Astex Pharmaceuticals, Inc. by Otsuka Group
  • 19.11. Celgene Corporation
  • 19.12. CTI BioPharma Corp.
  • 19.13. Cyclacel Pharmaceuticals, Inc.
  • 19.14. Daiichi Sankyo Company, Limited
  • 19.15. Eisai Co., Ltd.
  • 19.16. F. Hoffmann-La Roche AG
  • 19.17. GlaxoSmithKline plc
  • 19.18. Janssen Global Services, LLC
  • 19.19. Jazz Pharmaceuticals PLC
  • 19.20. Johnson & Johnson Services, Inc.
  • 19.21. MEI Pharma, Inc.
  • 19.22. Merck & Co., Inc.
  • 19.23. Merus N.V.
  • 19.24. Novartis AG
  • 19.25. Pfizer Inc.
  • 19.26. Sanofi S.A.
  • 19.27. Sun Pharmaceutical Industries Ltd.
  • 19.28. Takeda Pharmaceutical Company Limited
  • 19.29. Teva Pharmaceutical Industries Ltd.
  • 19.30. The Bristol Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)